MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.70466

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2025

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALD.

Tamaki Nobuharu, Kimura Takefumi, Wakabayashi Shun-Ichi, Tanaka Naoki, Izumi Namiki, Loomba Rohit, Kurosaki Masayuki

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Steatotic liver disease (SLD), which encompasses metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD) and alcohol-associated liver disease (ALD), is recognised as a risk factor for gastrointestinal cancers. However, the comparative risk of gastrointestinal cancers among MASLD, MetALD and ALD remains unclear.

METHODS

We used a Japanese, nationwide, health insurance claims database between 2005 and 2024, encompassing approximately 10 million individuals and conducted a nationwide, population-based cohort study including 978,607 patients with MASLD, 366,152 with MetALD, 152,721 with ALD and 4,884,398 control individuals. The primary outcome was the incidence of gastrointestinal cancers, including hepatocellular carcinoma (HCC), biliary tract cancer, oesophageal cancer, gastric cancer, colorectal cancer and pancreatic cancer.

RESULTS

Compared to controls, the adjusted hazard ratios (HRs) for HCC ranged from 3.55 to 5.39 across the MASLD, MetALD and ALD and from 1.45 to 1.66 for biliary tract cancer. The risks of both HCC and biliary tract cancer were significantly elevated in all SLD subgroups compared to controls. For oesophageal, gastric and colorectal cancers, the aHRs ranged from 0.75 to 1.26 in MASLD, from 1.09 to 1.44 in MetALD and from 1.13 to 2.48 in ALD, indicating increasing risk with greater alcohol consumption. The risk of pancreatic cancer was comparable to that in controls for both MetALD and ALD.

CONCLUSIONS

Patients with SLD, including MASLD, MetALD and ALD, have a significantly higher risk of gastrointestinal cancers compared to the controls. The degree of risk varies according to the underlying liver disease subtype, particularly in relation to alcohol consumption. These findings underscore the importance of implementing risk-stratified cancer screening strategies in patients with SLD.

Для цитирования: Tamaki Nobuharu, Kimura Takefumi, Wakabayashi Shun-Ichi, Tanaka Naoki, Izumi Namiki, Loomba Rohit, Kurosaki Masayuki. Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD, MetALD and ALD.. Alimentary pharmacology & therapeutics. 2025. DOI: 10.1111/apt.70466.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.